Dishman Carbogen Amcis LtdQ1 FY23Pharmaceuticals & Biotechnology

Dishman Carbogen Amcis Ltd

Q1 FY23 Earnings Call Analysis

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

Yes

Capex

Yes

4 of 5 growth signals are positive — a strong management growth story.

Revenue guidance

Category 3

→The company anticipates a top-line growth of 12% to 15% CAGR over the next 5 years.
→Management is confident of sustainable growth, having addressed past cyclical challenges, improving manufacturing quality, manpower, and processes.
→The Bavla facility, despite EDQM inspection delays, is expected to perform strongly with revenues higher than the last financial year and no seasonality impact.
→Investment in new capacities like the cells facility is already showing promising progress with revenue reaching 50% of the second-year target shortly after launch.
→The company foresees double-digit growth in top line and over 20% growth in EBITDA, aiming to return to pre-2019 profitability levels.
→Long-term growth confidence is based on the industry’s significant gap and contract research and manufacturing demand, expected to last at least two decades.

Category 1

→The company anticipates top-line growth of 12% to 15% CAGR over the next 5 years (Page 11).
→Targeting EBITDA margin improvement back to 25%-26% levels seen in 2019-2020 (Page 10).
→Expecting at least 20% plus EBITDA growth in FY '24 compared to FY '23, supporting significant PAT improvement (Page 9).
→Confident about consistent top-line and profitability growth, moving into positive profit territory in the current fiscal year (Page 9).
→Growth attributed to resolving past challenges (e.g., EDQM inspection delays) and ramp-up of the Bavla facility alongside strong overseas subsidiary performance (Page 10).
→Projected bright future over next two decades due to market gaps and strategic investments (Page 22).

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Dishman Carbogen Amcis Ltd and 1,400+ other companies.

Yes

→No major new CAPEX programs planned currently; only maintenance CAPEX (about 4–5% of gross block) ongoing.
→Debt increased in the last financial year due to expansion projects; no further significant increase in net debt is expected going forward.
→The company prefers to use debt as a financial tool rather than equity because cost of debt is lower than equity.
→There was a suggestion to deleverage and focus on paying down debt before incurring growth CAPEX, but the company intends to keep debt on books for leverage and strategic reasons.
→No explicit mention of impending new fundraising through debt or equity in the near term.
→Related party loan repayment is planned to clear before fiscal year-end, reducing related-party exposures and potentially impacting debt profile.

Yes

→Carbogen Amcis has a very strong order book as of FY '23.
→The company completed almost all one-off write-offs in FY '23.
→They are confident of achieving at least double-digit top-line growth in FY '24.
→EBITDA growth is expected to be aggressive, targeting 20%+ growth compared to FY '23.
→This strong order book and growth outlook position the company on a significantly positive trajectory for profitability (PAT).
→The management is positive about consistent growth and a strong pipeline supporting future orders, despite historical cyclicality and challenges.

Yes

→Most major CAPEX projects outside India are completed, including the new French facility (~$50 million), Swiss ADC expansion, and Indian lab and infrastructure upgrades.
→Future CAPEX will mainly be maintenance-related, around 4-5% of the gross block, estimated at CHF 35-40 million annually for FY '24 and FY '25.
→A significant upcoming expense is the digital transformation project implementing SAP across Carbogen Amcis, aimed at streamlining operations and delivering cost benefits long-term.
→The Hunzenschwil facility expansion project is currently on hold, with the land procured and preliminary engineering completed; no additional debt is planned to finance this at present.
→Management views these investments as strategic, enabling long-term growth and enhanced manufacturing capabilities, particularly in formulations and injectable products.
→No immediate major new CAPEX beyond maintenance and digital transformation; growth CAPEX to be reconsidered upon reaching revenue milestones (~Rs. 3,200-3,500 crore).

How does Dishman Carbogen Amcis Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Dishman Carbogen Amcis Ltd

Rev 3Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Dishman Carbogen Amcis Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.